Search

everythinglearnresearchcommunity

for

Search:↓

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

The user experienced significant hair regrowth in 5 weeks using Minoxidil, Finasteride, Dutasteride, biotin, collagen, derma stamping, and a mixture of oils, leading others to label them a "hyper responder." Some users advised caution with microneedling frequency to avoid potential scarring.

The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

User asks if mixing RU58841 solution with Serioxyl is okay for better scalp coverage and worries about reduced effects.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.

The conversation discusses hair shedding after starting a treatment regimen including topical dutasteride, RU58841, minoxidil, and keto shampoo. Shedding is considered normal, and users suggest adjustments like increasing dutasteride dosage or using oral medications for better results.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

A user shared their experience of getting 1400 hair grafts 5 months post-op with Dr. Vikram Jayaprakash, mentioning they have been using finasteride for 2.5 years. The responses include compliments on the results and questions about the cost and current treatments.

The user is experiencing worsening hair loss despite using oral finasteride, oral minoxidil, microneedling, keto shampoo, and supplements for seven months. They are concerned about continued shedding and lack of regrowth, and are considering adding topical minoxidil to their routine.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A 21-year-old has been using finasteride for nearly a year with positive results for hair loss. His parents found his stash, misunderstood the risks, and are forcing him to dispose of it, leading him to seek advice on handling the situation.

The user is experiencing severe hair shedding while on finasteride and plans to start using ketoconazole shampoo to address a greasy, waxy scalp buildup. They are seeking additional advice for managing hair loss.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.